

10 Supplementary figure 1. Schematic diagram of animal models. A. Preparing: Mouse anaesthesia, ear tag, skin preparing; B.Incision: A 1cm length incision along the 11 mid-line by sharp dissection was maken and the periosteum over the calvarium was 12 exposed; C: With blunt separating cranial periosteum, the surface of cranial bones 13 was exposed, using periosteal elevator and hemostatic forceps and a $1 \text{cm} \times 1 \text{cm}$ area 14 around the mid-line crossing the front and bregma bone in the cranium of mouse was 15 obtained in every mouse; D: Particle embedding; E: Closing the incision; F 16 Botezomib (BTZ) administration: mice were locally subcutaneously injected with 17 PBS or/and 0.1nM) of BTZ at each middle point of the edges of the surgical square 18 area to make sure the drug cover the whole surgical area (arrow) three injections/week 19 for two week. 20

- 21
- 22
- 23 24
- 25
- 26
- 27



Supplementary figure 2. Biological screens. The biological screens of the proportion of normal, early apoptosis, late apoptosis and death of RAW264.7 cells cocultured with or without Ti, UHMWPE particles and 0.5umol/ml BTZ for 72 hours in flow cytometry assay. Different sizes of Ti and UHMWPE (A: Ti-n+P-1; B: Ti-n+P-s; C: Ti- μ +P-1; D: Ti- μ +P-s) were mixed and co-cultured with cells. (Ti- μ : 5 μ m; Ti-n: 21nm; P-s: 40-48 μ m; P-1: 155 μ m).

A: Ti-n+P-l groups: control, 50 μ g/ml of Ti-n particles, 50 μ g/ml of P-l particles,10 μ g/ml of Ti-n particles; 10 μ g/ml of P-l particles, 10 μ g/ml of Ti-n mixed with P-l, (Ti:P-l=1:1), 10 μ g/ml of Ti-n mixed with P-l(Ti:P-l=1:3), 10 μ g/ml of Ti-n mixed with P-l (Ti:P-l=3:1) and 20 μ g/ml of Ti-n mixed with P-l (Ti:P-l=1:1) with or without BTZ (0.5nmol/ml).

B: Ti-n+P-s groups: control, 50 μ g/ml of Ti-n particles, 50 μ g/ml of P-s particles, 10 μ g/ml of Ti-n particles, 10 μ g/ml of P-s particles, 10 μ g/ml of Ti-n mixed with P-s (Ti:P-s=1:1), 10 μ g/ml of Ti-n mixed with P-s (Ti:P-s=1:3), 10 μ g/ml of Ti-n mixed with P-s (Ti:P-s=3:1) and 20 μ g/ml of Ti-n mixed with P-s (Ti:P-s=1:1) with or without BTZ (0.5nmol/ml).

C: Ti- μ +P-l groups: control, 50 μ g/ml of Ti- μ particles, 50 μ g/ml of P-l particles,10 μ g/ml of Ti- μ particles, 10 μ g/ml of Ti- μ mixed with P-l,

(Ti:P-l=1:1), 10 μg/ml of Ti-μ mixed with P-l (Ti:P-l=1:3), 10 μg/ml of Ti-μ mixed
 with P-l (Ti:P-l=3:1) and 20 μg/ml of Ti-μ mixed with P-l (Ti:P-l=1:1) with or
 without BTZ (0.5nmol/ml).

D: Ti-μ+P-s groups: control, 50 µg/ml of Ti-µ particles, 50 µg/ml of P-s particles,
10 µg/ml of Ti-µ particles, 10 µg/ml of P-s particles, 10 µg/ml of Ti-µ mixed with P-s,
(Ti:P-s=1:1), 10 µg/ml of Ti-µ mixed with P-s (Ti:P-s=1:3), 10 µg/ml of Ti-µ mixed
with P-s (Ti:P-s=3:1) and 20 µg/ml of Ti-µ mixed with P-s (Ti-µ:P-s=1:1) with or
without BTZ (0.5nmol/ml).

```
10
```



Supplementary figure 3. Effects of BTZ and Ti Particles on Raw 264.7. RAW264.7 cells co-cultured with or without Ti-µ, Al-n particles and 0.5umol/ml BTZ for 3 days. (Bar = 0.1 mm. Group: control, Ti- μ (10 μ g/ml), Al-n (10 μ g/ml), 10 μ g/ml of Ti-µ mixed with Al-n (Ti-µ:Al-n=1:1), 20 µg/ml of Ti-µ mixed with Al-n (Ti-µ:Al-n=1:1), Ti-µ 50µg/ml with or without 0.5 nmol/ml BTZ, and Al-n 50µg/ml with or without 0.5 nmol/ml BTZ.



17 Supplementary figure 4. mRNA screen of TNF- α and IL-1β expression

18 A: A mRNA screen of TNF- α and IL-1 β expression of macrophage under the 19 stimulation of different concentrations of nano scale TiO₂ particles.

20 B: A mRNA screen of TNF- α and IL-1 β expression of macrophage under the

21 stimulation of different concentrations of micro scale of Al₂O₃ particles.

- **C-D**: Quantification of the Figure 5 C.
- 23 E-G: Quantification of the Figure 5 F.





2 3 4 Supplementary figure 5. BCA assay: RAW 264.7 cells were co-cultured with pure 5 or mixed particles as the following groups such as Control, Ti-µ 10, Al-n 10, Ti-µ 50, Al-n 50, Ti-µ+Al-n 20 (1:1), Ti-µ+ Al-n 10 (3:1), Ti-µ+ Al-n 10 (1:1), Ti-µ+ Al-n 10 6 7 (1:3) for three day. And the cells were then harvested with lysed in cold RIPA buffer 8 with protease inhibitors (Beyotime, Shanghai, China) to extract proteins. Then, The whole cell protein concentration in the lysates were centrifuged 4°C. The lysates from 9 each sample were detected with a BCA Protein Assay Kit (Biyotime Biotechnology, 10 P0012). 11



Supplementary figure 6. The mimic mechanism of Al-n particles and BTZ could
reduce the inflammatory and aseptic absorption caused by Ti-µ particles.

31

1

12